AN2 Therapeutics, Inc. (ANTX) — Financial statements
Income statement, balance sheet, and cash flow for AN2 Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.08 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↑100.0% | -0.08 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 25↓38.8% | 40↓26.2% | 55↑85.9% | 30↑74.6% | 17 | |
| General & Administrative Expenses | 13↓5.2% | 14↓4.7% | 15↑15.8% | 13↑173.2% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 13↓5.2% | 14↓4.7% | 15↑15.8% | 13↑173.2% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 38↓30.1% | 55↓21.7% | 70↑65.1% | 42↑95.5% | 22 | |
| Total Costs & Expenses | 38↓30.1% | 55↓21.7% | 70↑64.8% | 42↑95.9% | 22 | |
| Operating Results | ||||||
| Operating Income | -38↑30.1% | -55↑21.7% | -70↓64.8% | -42↓95.9% | -22 | |
| Depreciation & Amortization | 0.00↓100.0% | 55↓21.7% | 70↑90335.1% | 0.08 | 0.00 | |
| EBITDA | -38↓1278.8% | 3↓34.1% | 5↑112.0% | -41↓89.5% | -22 | |
| EBIT | -38↑25.7% | -51↑20.7% | -65↓58.1% | -41↓89.8% | -22 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓46.3% | 5 | 0.00↓100.0% | 0.84↑1113.0% | 0.07 | |
| Interest Income | 3↓46.3% | 5 | 0.00↓100.0% | 1↑1858.0% | 0.07 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.51 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -3↑34.1% | -5↓275.4% | -1 | 0.00 | |
| Other Income / Expenses | 3↓9.2% | 3↓34.1% | 5↑275.4% | 1↑4112.9% | 0.03 | |
| Income Before Tax | -35↑31.5% | -51↑20.7% | -65↓58.1% | -41↓90.1% | -22 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -35↑31.5% | -51↑20.7% | -65↓58.1% | -41↓90.1% | -22 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -35↑31.5% | -51↑20.7% | -65↓58.1% | -41↓90.1% | -22 | |
| Bottom-Line Net Income | -35↑31.5% | -51↑20.7% | -65↓51.3% | -43↓52.5% | -28 | |
| EPS (Basic) | -1.16↑32.6% | -1.72↑37.2% | -2.74↑1.8% | -2.79↓86.0% | -1.50 | |
| EPS (Diluted) | -1.16↑32.6% | -1.72↑37.2% | -2.74↑1.8% | -2.79↓86.0% | -1.50 | |
| Weighted Average Shares | 30↑1.3% | 30↑26.4% | 24↑53.8% | 15↓18.1% | 19 | |
| Weighted Average Diluted Shares | 30↑1.3% | 30↑26.4% | 24↑53.8% | 15↓18.1% | 19 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.